medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2023; 28 (2)


Comparative efficacy of first and second generation long-acting injectable antipsychotic in schizophrenic patients: a systematic review and network meta-analysis

Saucedo-Uribe E, González-Mallozzi PJ, Medrano-Garza RR, Díaz González-Colmenero F, Carranza-Navarro F, Castillo-Morales PL, Leyva-Camacho PC, Herrera-Montemayor Y, Vidal-Tijerina M, Enríquez-Navarro MK, Medrano SB, Fernández-Zambrano SM, Mancías- Guerra CM, Saucedo-Mancías CL, Sánchez-Ramírez MR

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 35-43
Archivo PDF: 570.73 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brown A, Lau F. Chapter 2 - A review of the epidemiology ofschizophrenia. Handb Behav Neurosci. 2016;23:17-30.

  2. World Health Organization. Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

  3. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, etal. Grand challenges in global mental health. Nature. 2011,

  4. 475:7-10.4. Karadag F, Sengul CB, Enli Y, Karakulah K, Alacam H, KaptanogluB et al. Relationship between serum bilirubin levels and metabolicsyndrome in patients with schizophrenia spectrum disorders. ClinPsychopharmacol Neurosci. 2017;15(2):153-62.

  5. Kim YK, Choi J, Park SC. A novel bio-psychosocial-behavioraltreatment model in schizophrenia. Int J Mol Sci. 2017;18(4):734.

  6. Tripathi A, Kar SK, Shukla R. Cognitive deficits in schizophrenia:Understanding the biological correlates and remediationstrategies. Clin Psychopharmacol Neurosci. 2018;16(1):7-17.

  7. Chesney E, Goodwin G, Fazel S. Risks of all-cause and suicidemortality in mental disorders: a meta-review. World Psychiatry.2014;13(2):153-60.

  8. Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L.Interventions to improve adherence to antipsychotic medicationin patients with schizophrenia-A review of the past decade.Eur Psychiatry [Internet]. 2012;27(1):9-18. doi: 10.1016/j.eurpsy.2011.02.005

  9. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Longactinginjectable versus oral antipsychotics in schizophrenia: Asystematic review and meta-analysis of mirror-image studies. JClin Psychiatry. 2013;74(10):957-65.

  10. Leucht C, Heres S, Kane J, Kissling W, Davis J, Leucht S. Oralversus depot antipsychotic drugs for schizophrenia--a criticalsystematic review and meta-analysis of randomised long-termtrials. Schizophr Res. 2011; 127(1-3):83-92.

  11. Park SC, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK, et al.Comparative efficacy and safety of long-acting injectable andoral second-generation antipsychotics for the treatment ofschizophrenia: A systematic review and meta-Analysis. ClinPsychopharmacol Neurosci. 2018; 16(4):361-75.

  12. Kishi T, Matsunaga S, Iwata N. Mortality risk associated withlong-acting injectable antipsychotics: A systematic review andmeta-analyses of randomized controlled trials. Schizophr Bull.2016; 42(6):1438-45.

  13. Gentile S. Discontinuation rates during long-term, secondgenerationantipsychotic long-acting injection treatment: Asystematic review. Psychiatry Clin Neurosci. 2019;73(5):216-30.

  14. Saucedo E, Carranza F, Fernanda A, Medrano G, IscelyK, Cervantes G, et al. Preliminary efficacy and tolerabilityprofiles of first versus second-generation long-acting injectableantipsychotics in schizophrenia : A systematic review and metaanalysis.J Psychiatr Res. 2020; 129:222-33.

  15. Falotico R, Quatto P. Fleiss’ kappa statistic without paradoxes.Qual Quant. 2015; 49:463-70.

  16. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitionsof response and remission in schizophrenia: Recommendationsfor their use and their presentation. Acta Psychiatr Scand Suppl.2009; (438):7-14.

  17. Schennach-Wolff R, Seemüller FH, Mayr A, Maier W, KlingbergS, Heuser I, et al. An early improvement threshold to predictresponse and remission in first-episode schizophrenia. Br JPsychiatry. 2010;196(6):460-6.

  18. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al., editors. Cochrane Handbook for Systematic Reviews ofInterventions version 6.0 (updated July 2019). Cochrane; 2019.www.training.cochrane.org/handbook

  19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality ofevidence and strength of recommendations. BMJ. 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.

  20. Puhan MA, Murad MH, Li T, Singh JA, Kessels AG, Guyatt GH, et al. A GRADE Working Group approach for rating the quality of treatmenteffect estimates from network meta-analysis. BMJ. 2014;349:g5630:1-10. doi: 10.1136/bmj.g5630

  21. Marder SR, Kirkpatrick B. Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol[Internet. 2014;24(5):737-43. doi: 10.1016/j.euroneuro.2013.10.016

  22. McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, et al. Effectiveness of paliperidone palmitate vs haloperidoldecanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA - J Am Med Assoc. 2014; 311(19):1978-86.

  23. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patientswith acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol.2010;25(5):247-56.

  24. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate andrisperidone long-acting injectable in adults with schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry. 2011; 35(1):218-26.doi: 10.1016/j.pnpbp.2010.11.008




2020     |     www.medigraphic.com